Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
The FDA has selected Eli Lilly and Regeneron for a pilot program designed to accelerate the review process for new pharmaceutical manufacturing facilities.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Eli Lilly and Regeneron are among the initial companies selected to participate in the program. Coverage from outlets including CNBC, TipRanks, GuruFocus, Yahoo, and the Baton Rouge Business Report emphasizes the program's primary objective: accelerating the timeline for getting new medicines to market.
Reports highlight this move as a strategic shift in FDA regulatory operations. Future updates will likely track the operational impact of the PreCheck pilot on drug manufacturing timelines.
Coverage does not yet specify the duration of the pilot or if additional companies will be selected for the program.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (83% supported) Updated 42m ago.
Quick answers
Which companies were selected for the FDA pilot program?
Eli Lilly and Regeneron are among the first companies confirmed for the initiative.
What is the goal of the FDA PreCheck program?
The program aims to expedite the review process for new manufacturing facilities to help get medicines to market faster.
Are there other companies participating in the program?
Current coverage specifies Eli Lilly and Regeneron but does not list other participants.
Coverage (7)
- Kriya Selected for FDA PreCheck Pilot Program Business Wire · 4h ago
- Lilly, Regeneron selected for US program to review new manufacturing plants faster, CNBC reports Reuters · 4h ago
- FDA to Expedite Review of Eli Lilly’s (LLY) New Manufacturing Facilities TipRanks · 4h ago
- Eli Lilly (LLY) Joins FDA PreCheck Pilot Program for Manufacturi GuruFocus · 4h ago
- Lilly, Regeneron selected for US program to review new manufacturing facilities faster, CNBC reports Yahoo · 4h ago
- A new FDA strategy aims to get medicines to the market faster Baton Rouge Business Report · 4h ago
- Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities CNBC · 4h ago
Topics
Related trends
Potato chip recall upgraded to highest FDA risk level over salmonella concerns
The FDA has classified a voluntary recall of specific Zapp's and Dirty potato chip varieties as a Class I risk due to potential salmonella contamination.
Eli Lilly Leads 5 Stocks Near Buy Points As The Market Rally Rotates
Eli Lilly’s stock surges to record highs as EU approvals and market rotation fuel investor optimism
China’s Industrial Profit Gains Dip in Sign of Weakness
China’s industrial profits grow but show signs of slowing—what’s driving the shift?
One Specific Blood Protein Can Identify Dementia Risk Decades Before Diagnosis
A single blood protein could redefine Alzheimer’s detection—decades before symptoms appear.
European Regulator Calls for Amgen’s Tavneos to Have Authorization Revoked
European regulators have recommended revoking marketing authorization for the Amgen drug Tavneos due to concerns regarding the reliability of study data.
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026
Eli Lilly’s stock surges as EU panel fast-tracks approvals for two blockbuster drugs, reshaping investor and patient expectations